Susquehanna International Group, LLP Mirum Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$33.68 - $44.74 $458,048 - $608,464	13,600 New	13,600 $530,000
Q1 2024 May 07, 2024	BUY	$24.92 - $30.02 $82,236 - $99,066	3,300 Added 46.48%	10,400 $261,000
Q4 2023 Feb 14, 2024	SELL	$27.14 - $34.93 $784,346 - $1.01 Million	-28,900 Reduced 80.28%	7,100 $209,000
Q3 2023 Nov 14, 2023	BUY	$24.63 - $32.85 $886,680 - $1.18 Million	36,000 New	36,000 $1.14 Million
Q1 2022 May 16, 2022	BUY	$15.5 - $23.93 $6,200 - $9,572	400 Added 2.86%	14,400 $317,000
Q4 2021 Feb 14, 2022	SELL	$13.05 - $19.35 $130,500 - $193,500	-10,000 Reduced 41.67%	14,000 $223,000
Q3 2021 Nov 15, 2021	BUY	$13.95 - $20.18 $334,800 - $484,320	24,000 New	24,000 $478,000

190

54M

177K

167K

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.64B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.